中国计划生育和妇产科
中國計劃生育和婦產科
중국계화생육화부산과
Chinese Journal Of Family Planning & Gynecotokology
2015年
11期
53-57
,共5页
李菁%沈立翡%朱岚%蔡蕾
李菁%瀋立翡%硃嵐%蔡蕾
리정%침립비%주람%채뢰
上皮性卵巢恶性肿瘤%间隔减瘤术%新辅助化疗%直接肿瘤减灭术
上皮性卵巢噁性腫瘤%間隔減瘤術%新輔助化療%直接腫瘤減滅術
상피성란소악성종류%간격감류술%신보조화료%직접종류감멸술
epithelial ovarian cancer%interval debulking surgery%neoadjuvant chemotherapy%primary debulking surgery
目的:探讨新辅助化疗联合间隔减瘤术( neoadjuvant chemotherapy followed by interval debulking surgery,NACT/IDS)在晚期卵巢癌中的临床应用价值。方法回顾性分析上海交通大学附属瑞金医院2000年6月至2013年1月109例IIIc和IV期晚期卵巢癌患者资料,将53例直接行肿瘤减灭术( primary debulking surgery,PDS)患者纳入PDS组,将56例行NACT/IDS患者纳入NACT/IDS组,比较两组的生存率及围手术期情况。结果两组患者术后总生存率( overall survival, OS)和无病进展期( progression-free survival, PFS)比较差异均无统计学意义(P>0.05)。 NACT/IDS组手术切除率(53.6%)明显高于PDS组(43.4%)(P<0.05);NACT/IDS组手术出血量、术后恢复、并发症的发生情况优于PDS组(P<0.05)。结论 NACT/IDS增加了手术切除率,减少了手术创伤,术后生存率与PDS无明显差异。在Ⅲc期和Ⅳ期卵巢癌患者,并非强调直接行PDS,NACT/IDS是有效的治疗方法。
目的:探討新輔助化療聯閤間隔減瘤術( neoadjuvant chemotherapy followed by interval debulking surgery,NACT/IDS)在晚期卵巢癌中的臨床應用價值。方法迴顧性分析上海交通大學附屬瑞金醫院2000年6月至2013年1月109例IIIc和IV期晚期卵巢癌患者資料,將53例直接行腫瘤減滅術( primary debulking surgery,PDS)患者納入PDS組,將56例行NACT/IDS患者納入NACT/IDS組,比較兩組的生存率及圍手術期情況。結果兩組患者術後總生存率( overall survival, OS)和無病進展期( progression-free survival, PFS)比較差異均無統計學意義(P>0.05)。 NACT/IDS組手術切除率(53.6%)明顯高于PDS組(43.4%)(P<0.05);NACT/IDS組手術齣血量、術後恢複、併髮癥的髮生情況優于PDS組(P<0.05)。結論 NACT/IDS增加瞭手術切除率,減少瞭手術創傷,術後生存率與PDS無明顯差異。在Ⅲc期和Ⅳ期卵巢癌患者,併非彊調直接行PDS,NACT/IDS是有效的治療方法。
목적:탐토신보조화료연합간격감류술( neoadjuvant chemotherapy followed by interval debulking surgery,NACT/IDS)재만기란소암중적림상응용개치。방법회고성분석상해교통대학부속서금의원2000년6월지2013년1월109례IIIc화IV기만기란소암환자자료,장53례직접행종류감멸술( primary debulking surgery,PDS)환자납입PDS조,장56례행NACT/IDS환자납입NACT/IDS조,비교량조적생존솔급위수술기정황。결과량조환자술후총생존솔( overall survival, OS)화무병진전기( progression-free survival, PFS)비교차이균무통계학의의(P>0.05)。 NACT/IDS조수술절제솔(53.6%)명현고우PDS조(43.4%)(P<0.05);NACT/IDS조수술출혈량、술후회복、병발증적발생정황우우PDS조(P<0.05)。결론 NACT/IDS증가료수술절제솔,감소료수술창상,술후생존솔여PDS무명현차이。재Ⅲc기화Ⅳ기란소암환자,병비강조직접행PDS,NACT/IDS시유효적치료방법。
Objective To explore the application value of neoadjuvant chemotherapy followed by interval debulking surgery ( NAC/IDS) in treating patients with advanced epithelial ovarian cancer ( EOC) . Methods We retrospectively reviewed 109 patients with stage IIIC or IV EOC treated at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from June 2000 to January 2013. 53 patients underwent PDS were selected into PDS group, while 56 patients underwent NAC/IDS were selected into NAC/IDS group, the survival rate and perioperative morbidity were compared between two groups. Results No difference in overall survival (OS) or progression-free survival (PFS) were observed between NAC/IDS group and PDS group (P>0. 05). The optimal debulking rate of NAC/IDS group (53. 6 %) was significantly higher than that of the PDS group (43. 4 %) (P<0. 05). The NAC/IDS group had significantly less intraoperative blood loss, lower complication rate, and earlier recovery compared to PDS group ( P<0. 05). Conclusion NAC/IDS may increase the resection rate and reduce the surgical trauma, without significantly difference in survival rate compared with PDS. NAC/IDS may be a valuable alternative treatment for patients with stage IIIC or IV EOC.